HER2+ Breast Cancer | Specialty

Review of Clinical Data on Palbociclib in Breast Cancer

February 2nd 2016

The Role of Fulvestrant in Metastatic HR+ Breast Cancer

February 2nd 2016

Appropriate Duration of Endocrine Therapy in Breast Cancer

February 2nd 2016

Managing Luminal A and Luminal B Breast Cancer

February 2nd 2016

Genomic Testing in Breast Cancer

February 2nd 2016

Treating Intermediate Risk Individuals with Breast Cancer

February 2nd 2016

HER2 Subtype Offers Clues for Individualizing Breast Cancer Care

January 29th 2016

One-third of patients previously identified as having HER2-positive breast cancer were found to also have a luminal subtype that was resistant to chemotherapy and trastuzumab but still sensitive to the triplet neoadjuvant regimen of pertuzumab, trastuzumab, and chemotherapy.

Less May Be More: Refining HER2-Positive Breast Cancer Care

January 26th 2016

Mothaffar Rimawi, MD, discusses key recent data with HER2-targeted agents and the need to identify patients for whom optimal care may mean de-escalating therapy.

Dr. Blackwell on Margetuximab for HER2+ Breast Cancer

January 19th 2016

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses the mechanism of action for margetuximab (MGAH22-01) and discusses its potential as a treatment of patients with HER2-positive breast cancer.

Prophylactic Loperamide Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer

December 22nd 2015

Grade 3 diarrhea occurred in 16% of patients treated with neratinib and prophylactic loperamide, representing a significant reduction compared with phase III findings from the ExteNET trial.

Effective Management and Prevention of Neratinib-Induced Diarrhea

December 18th 2015

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Gargi Basu on Alterations in the Cell Cycle Checkpoint Pathway in Breast Cancer

December 17th 2015

Gargi D. Basu, PhD, senior director of Clinical Curation, Ashion Analytics, discusses a study that examined alterations in the cell cycle checkpoint pathway in patients with breast cancer.

Neratinib DFS Benefit Sustained in 3-Year ExteNET Update

December 12th 2015

The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.

T-DM1 Extends Survival in Heavily Pretreated HER2+ Breast Cancer

December 11th 2015

T-DM1 (ado-trastuzumab emtansine; Kadcyla) reduced the risk of death by 32% and improved median overall surviva by almost 7 months compared with physician's choice of therapy in heavily pretreated patients with HER2-positive advanced breast cancer.

Dr. Kolberg on Cost-Effectiveness of Pertuzumab in HER2-Positive Breast Cancer

December 10th 2015

Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses the cost-effectiveness of pertuzumab as a treatment for patients with HER2-positive breast cancer, based off of findings from a study published in the Journal of Clinical Oncology.

Expert Describes Discouraging Neoadjuvant Data in HER2+ Breast Cancer

December 10th 2015

Gunter von Minckwitz, MD, discusses less-than-encouraging results and what next steps lie ahead in neoadjuvant therapy regimens for HER2-positive breast cancer.

Dr. Whitworth on the Importance of Additional HER2 Subtyping

December 10th 2015

Pat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.

Prophylactic Intervention Improves Cardiac Safety in HER2-Positive Breast Cancer

December 10th 2015

Prophylactic administration of standard heart failure medications helped preserve left ventricular ejection fraction in patients treated with trastuzumab for HER2-positive metastatic breast cancer.

Hudis on ExteNET, APHINITY, and What's Next for Adjuvant HER2+ Breast Cancer

December 4th 2015

Clifford Hudis, MD, discusses the evolving adjuvant therapy options in HER2-positive breast cancer.

Missense HER2 Mutations May Not Respond to Targeted Therapies

November 24th 2015

Not all HER2 genes are capable of causing cancer growth or spread, and thus may also fail to predict response to anticancer drugs that target the gene.